iCAD (NASDAQ:ICAD) Issues Earnings Results

iCAD (NASDAQ:ICAD) released its quarterly earnings data on Thursday. The technology company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01, Morningstar.com reports. The firm had revenue of $7.33 million during the quarter, compared to the consensus estimate of $6.69 million. iCAD had a negative net margin of 36.24% and a negative return on equity of 54.45%.

Shares of ICAD traded down $0.09 during midday trading on Friday, hitting $6.74. 138,773 shares of the stock traded hands, compared to its average volume of 154,208. iCAD has a 1-year low of $2.42 and a 1-year high of $7.45. The company has a market capitalization of $129.83 million, a price-to-earnings ratio of -17.74 and a beta of 1.04. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.47 and a quick ratio of 1.33. The company’s 50 day simple moving average is $6.42.

Separately, ValuEngine downgraded shares of iCAD from a “buy” rating to a “hold” rating in a report on Thursday.

Institutional investors and hedge funds have recently made changes to their positions in the company. Advisor Group Inc. boosted its holdings in shares of iCAD by 96,087.0% during the fourth quarter. Advisor Group Inc. now owns 22,123 shares of the technology company’s stock valued at $82,000 after acquiring an additional 22,100 shares during the period. Spark Investment Management LLC acquired a new position in shares of iCAD during the first quarter valued at $185,000. Deutsche Bank AG boosted its holdings in shares of iCAD by 33.5% during the fourth quarter. Deutsche Bank AG now owns 35,923 shares of the technology company’s stock valued at $132,000 after acquiring an additional 9,023 shares during the period. Columbia Pacific Advisors LLC boosted its holdings in shares of iCAD by 218.0% during the first quarter. Columbia Pacific Advisors LLC now owns 63,600 shares of the technology company’s stock valued at $329,000 after acquiring an additional 43,600 shares during the period. Finally, EAM Global Investors LLC acquired a new position in shares of iCAD during the first quarter valued at $984,000. 18.98% of the stock is owned by institutional investors.

iCAD Company Profile

iCAD, Inc provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy.

Further Reading: Using other technical indicators with support levels

Earnings History for iCAD (NASDAQ:ICAD)

Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.